Mi­rati’s drug sitra­va­tinib flops PhI­II in com­bo with Op­di­vo for cer­tain lung can­cer

Mi­rati Ther­a­peu­tics’ path to a sec­ond drug ap­proval will like­ly have to wait. The San Diego biotech com­pa­ny said Wednes­day that its in­ves­ti­ga­tion­al lung can­cer drug failed a Phase III tri­al test­ing it in com­bi­na­tion with Bris­tol My­ers Squibb’s Op­di­vo.

The drug, sitra­va­tinib, and Op­di­vo weren’t bet­ter than the chemo drug do­c­etax­el at keep­ing pa­tients alive, Mi­rati said in a press re­lease. The spec­trum-se­lec­tive ki­nase in­hibitor missed the pri­ma­ry goal of over­all sur­vival in pa­tients with sec­ond- or third-line ad­vanced non-squa­mous, non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER